Overall survival · palliative participants with AC of the esophagus
Summary of findings table (subcomparison 5): chemotherapy or… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with AC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 5): chemotherapy or… changes progression‐free survival compared with control intervention alone (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with AC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 5): chemotherapy or… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with AC of the esophagus
1 finding from 1 review
Overall survival · palliative participants with SCC of the esophagus
Summary of findings table (subcomparison 6): chemotherapy or… leads to lower overall survival compared with control intervention alone (high certainty).
1 finding from 1 review
Progression‐free survival · palliative participants with SCC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 6): chemotherapy or… changes progression‐free survival compared with control intervention alone (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with SCC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 6): chemotherapy or… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Quality of life · palliative participants with SCC of the esophagus
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in progression‐free survival (PFS) compared with PLD alone (low certainty).
1 finding from 1 review
Quality of life · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy probably leads to higher overall severe adverse events (grade ≥ 3) compared with PLD alone (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with PLD alone (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy probably leads to lower hand‐foot syndrome (grade ≥ 3) compared with PLD alone (moderate certainty).
1 finding from 1 review
Neurological (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in neurological (grade ≥ 3) compared with PLD alone (low certainty).
1 finding from 1 review
Altered fractionation radiotherapy plus chemotherapy vs Chemoradiotherapy with standard (conventional) fractionation
Outcome not reported · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…
The review found no eligible studies for this question.
1 finding from 1 review
Death (all causes)
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).
1 finding from 1 review
Prostate cancer‐specific death5
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower prostate cancer‐specific death5 compared with ADT only (moderate certainty).
1 finding from 1 review
Time to progression
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty).
1 finding from 1 review